Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes - The New England Journal of Medicine - 2015
Brief Summary:
In this industry sponsored trial, empagliflozin reduced the rate of CV events and slowed the progression of kidney disease among patients with T2DM and high CV risk.Reference: http://www.ncbi.nlm.nih.gov/pubmed/26378978
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you